The US Food and Drug Administration’s TEMPO Pilot Signals a New Regulatory Approach for AI-Enabled Medical Devices
Journal of Medical Internet Research · 30.09.2026 · 28 · e112391-e112391
DOI: 10.2196/112391 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Internet Research, online erschienen am 30.09.2026. Verfasst von Tejas S Athni. Hauptthemen laut MEDLINE: United States Food and Drug Administration, Artificial Intelligence, Equipment and Supplies, Device Approval. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
As the pace of evolution and nature of AI-based technologies outgrow traditional frameworks for evaluation, regulatory bodies are developing new models to keep up. In this News and Perspectives article, JMIR Correspondent Tejas Athni reports on the US Food and Drug Administration’s (FDA’s) new Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot for AI-enabled medical devices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Förderung
- NIGMS NIH HHS
Zitieren
APA
Athni, T. S. (2026). The US Food and Drug Administration’s TEMPO Pilot Signals a New Regulatory Approach for AI-Enabled Medical Devices. Journal of Medical Internet Research, 28, e112391-e112391. https://doi.org/10.2196/112391
Vancouver
Athni TS. The US Food and Drug Administration’s TEMPO Pilot Signals a New Regulatory Approach for AI-Enabled Medical Devices. Journal of Medical Internet Research. 2026;28:e112391-e112391. doi:10.2196/112391
BibTeX
@article{Athni2026,
author = {Athni, Tejas S},
title = {The US Food and Drug Administration’s TEMPO Pilot Signals a New Regulatory Approach for AI-Enabled Medical Devices},
journal = {Journal of Medical Internet Research},
year = {2026},
volume = {28},
pages = {e112391--e112391},
doi = {10.2196/112391}
}
EUVIMED